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ABSTRACT 
Emulgels have emerged as a promising drug delivery system for the delivery of hydrophobic drugs. The objective of the study was to prepare 
emulgel of Dexibuprofen, a NSAID, using Carbapol 940 as a gelling agent. Clove oil and Mentha oil were used as penetration enhancers. The 
emulsion was prepared and it was added in gel base. The formulations were evaluated for rheological studies, spreading coefficient studies, 
bioadhesion strength, skin irritation studies, in vitro release, ex vivo release studies, anti-inflammatory activity and analgesic activity. 
Formulation showed comparable analgesic and anti-inflammatory activity when they compared with marketed diclofenac sodium gel. So, it can 
be concluded that topical emulgel of Dexibuprofen possess an effective anti-inflammatory and analgesic activity. 
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INTRODUCTION 
Several analgesic agents are available in the market in 
different topical preparations (e.g. creams, ointments, and 
powders for the purpose of local dermatological therapy. It 
is applied locally in mild uncomplicated dermatophyte and 
other cutaneous infections.1,2 Both oil-in-water and water-in-
oil emulsions are extensively used for their therapeutic 
properties and as vehicles to deliver various drugs to the 
skin. Emulsions possess a certain degree of elegance and are 
easily washed off whenever desired. They also have a high 
ability to penetrate the skin. In addition, the formulator can 
control the viscosity, appearance, and degree of greasiness 
of cosmetic or dermatological emulsions. Oil-in-water 
emulsions are most useful as water washable drug bases and 
for general cosmetic purposes, while water-in-oil emulsions 
are employed more widely for the treatment of dry skin and 
emollient applications.3 Gels for dermatological use have 
several favorable properties such as being thixotropic, 
greaseless, easily spreadable, easily removable, emollient, 
nonstaining, compatible with several excipients, and water-
soluble or miscible. Emulgels are emulsions, either of the oil-
in-water or water in- oil type, which are gelled by mixing 
with a gelling agent. They have a high patient acceptability 
since they possess the previously mentioned advantages of 
both emulsions and gels. Therefore, they have been recently 
used as vehicles to deliver various drugs to the skin.4,5 
MATERIALS AND METHODS  
Materials 
Dexibuprofen was obtained as a gift sample from Glenmark 
Pharmaceuticals Pvt. Ltd. Sinnar (Maharashtra). Carbopol 
940 was obtained from Loba chemicals Mumbai. Dialysis 
membrane was procured from Hi media, Mumbai. All other 
chemicals used were of analytical grade and were used 
without any further chemical modification.  
Solubility study 
Screening of excipients can be done by determining the 
equilibrium solubility of Dexibuprofen in different oils, 
surfactants and co-surfactants. The solubility of 
Dexibuprofen in different oils, surfactants and co-surfactants 
was determined using shake flask method. An excess 
amount of Dexibuprofen was added to each vial containing 
2ml of each excipient, and mixed by vortexing in order to 
facilitate proper mixing of Dexibuprofen with the vehicles. 
Vials were then shaken for 48 hrs in a Thermostatically 
controlled shaking water bath at 37 ± 1°C followed by 
equilibrium for 24 h. In order to separate the undissolved 
drug, the supersaturated sample was centrifuged at 3000 
Mahajan et al                                                                                                      Journal of Drug Delivery & Therapeutics. 2019; 9(2-s):330-342 
ISSN: 2250-1177                                                                                  [331]                                                                                 CODEN (USA): JDDTAO 
rpm for 10 min. The supernatant was then filtered using a 
membrane filter (0.45 μm, Whatman) and suitably diluted 
with methanol. The drug concentration was obtained via UV 
validated method at 221 nm.  
Preliminary screening of oils, surfactants 
The oil and surfactant having good solubilizing capacity for 
Dexibuprofen were selected for the studying there 
emulsifying properties. Briefly, 3ml of the surfactants were 
added to 3 ml of the oily phase. The mixture were gently 
heated at 40-50oC for homogenization of the components. 
Each mixture, 0.1 ml was then diluted with distilled water to 
10 ml in a stopper conical flask. Ease of emulsification was 
judged by time required to yield homogeneous emulsion 
when it diluted 100 times with distilled water with 
continuous stirring on magnetic stirrer. Emulsifying ability 
of the mixture was categorized in five classes on the basis of 
time required to form homogeneous emulsion (shown in 
Table 2). Emulsions were allowed to stand for 2 hr and 
emulsions were furthermore observed visually for any 
turbidity or phase separation. 
Preliminary screening of co-surfactant 
The selected oily phase and surfactant were used for further 
screening of the different co-surfactants for their 
emulsification ability. Mixtures of 3 ml of co-surfactant, 3 ml 
of surfactant and 3 ml of oil were prepared and evaluated in 
similar fashion as described in screening of surfactants. 
Drug-Excipient Compatibility Study 
After selection and screening of the oil, surfactant and co-
surfactant, next step is the physicochemical compatibility 
study of Dexibuprofen with excipients. The drug and 
excipient were equally distributed in glass ampoules. They 
were kept at room temperature 25oC and at 40oC/75% RH. 
The samples were drawn at intervals of 0, 2 and 4 weeks and 
analyzed for its physical appearance and drug stability by 
FT-IR. 
 
 
Preparation of emulgel  
Different formulations were prepared using varying amount 
of gelling agent and penetration enhancers. The method only 
differed in process of making gel in different formulation. 
The preparation of emulsion was same in all the 
formulations. The gel phase in the formulations was 
prepared by dispersing Carbopol 940 in purified water with 
constant stirring at a moderate speed using mechanical 
shaker, then the pH was adjusted to 6–6.5 using 
triethanolamine (TEA). The oil phase of the emulsion was 
prepared by dissolving span 20 in light liquid paraffin while 
the aqueous phase was prepared by dissolving Tween 20 in 
purified water. Methyl and propyl paraben were dissolved in 
propylene glycol whereas Dexibuprofen was dissolved in 
ethanol, and both solutions were mixed with the aqueous 
phase. Clove oil and mentha oil were mixed in oil phase. Both 
the oily and aqueous phases were separately heated to 70-
80oC, then the oily phase was added to the aqueous phase 
with continuous stirring until it got cooled to room 
temperature. The obtained emulsion was mixed with the gel 
in 1:1 ratio with gentle stirring to obtain the emulgel5. The 
composition of different formulations has been discussed in 
Table 11. 
Preformulation Study 
Organoleptic Characterization of Drug 
Melting Point: Melting point of the drug was found to be 
52oC - 54oC by using Capillary tube method. The readings 
were taken in triplicate and average was taken. The 
Reference melting point is in the range 49 oC - 53oC. 
Solubility: The solubility of Dexibuprofen in different 
solvents was determined using shake flask method. The 
results obtained were noted below in table 2. 
Table 1: Organoleptic Properties of Drug 
S. N. Parameter Observation 
1 Colour White to off white or Colorless 
2 Odor Odorless 
3 Appearance Solid crystalline powder 
 
Table 2: Solubility of Dexibuprofen in different solvent 
Sr. No. Solvent Solubility (mg/mL) at 25oC 
1 Distilled Water 0.020± 0.0023 
2 Cotton seed oil 0.027± 0.0054 
4 Oleic acid 0.043± 0.0046 
5 Sesame oil 0.050 ± 0.0006 
6 Castor oil 0.039 ± 0.0061 
7 Capryol-90 0.048± 0.0003 
8 Tween 20 0.045 ± 0.0033 
9 Tween 40 0.038± 0.0049 
10 Tween 60 0.046± 0.0036 
11 Tween 80 0.042± 0.0043 
12 Span 20 0.045±0.0021 
13 Span 80 0.042±0.0069 
14 Labrasol 0.042±0.0002 
15 Arachis oil 0.031±0.0010 
16 sunflower oil 0.049 ±0.0020 
17 Soybean oil 0.035±0.0012 
18 Polyethylene glycol 400 0.047±0.0064 
19 Polyethylene glycol 600 0.053 ±0.0009 
20 Transcutol P 0.042±0.0002 
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FT-IR Spectroscopy: 
FTIR spectrum (shown in Figure 1) of the drug sample showed all the characteristic IR peaks as reported in indicating the 
presence of functional groups of Dexibuprofen shown in table 3. 
 
Figure 1: FT-IR of Dexibuprofen 
Table 3: IR Interpretation of dexibuprofen 
Sr. No. Typical IR bands (cm-1) Interpretation 
Reference range Observed 
1 2960-2850 2955.04 C-H   stretching vibration 
2 2700-2500 2630.99 C=C stretching vibration 
3 1600-1450 1508.38 COOH stretching vibration 
 
UV Spectroscopy: 
Maximum absorbance of Dexibuprofen in methanol is shown 
in table 4 and figure 2. The λmax of Dexibuprofen in 
methanol was found to be at 221 nm this is characteristic 
property of Dexibuprofen in its pure form, hence it can be 
confirmed that obtained sample was authentic.  
Calibration curve of Dexibuprofen in methanol 
The calibration curve of the Dexibuprofen was prepared in 
methanol. Table 5 shows the absorbance at λmax 221 nm for 
different concentrations of Dexibuprofen and figure 3 shows 
calibration curve. The regression coefficient was found to be 
0.999 with slope value 0.052 and the Y intercept value 0.
 
 
Figure 2: UV- Spectra of Dexibuprofen in Methanol 
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Figure 3: Calibration curve of Dexibuprofen in Methanol 
Table 4: Maximum wavelength (λmax) of Dexibuprofen in Methanol. 
Solvent Wavelengths of maximum absorbance λmax (nm) 
Observed Reference 
Methanol 221 220 
 
 
Table 5: Calibration curve data of Dexibuprofen in 
Methanol 
Sr. No. Concentration 
(µg/ml) 
Absorbance 
1 2 0.107 
2 4 0.214 
3 6 0.315 
4 8 0.419 
5 10 0.530 
 
Table 6: Preliminary selected components from 
solubility study 
Preliminary selected Components for SMEDDS 
Oils Surfactants Co-surfactants 
Sesame oil Tween 60 PEG 600 
Sunflower oil Tween 20 PEG 400 
Oleic acid Tween 80 Span 20 
 
Excipients Screening 
Solubility study 
SMEDDS, an emulsion based formulation is a blend of oils 
and surfactants in suitable proportion that rapidly forms an 
oil in water (o/w) microemulsion with moderate gastric 
motility when exposed to the aqueous media present in the 
GIT. Co-surfactant and organic solvent can also be added 
sometime to improve the emulsification and solubility 
respectively. In order to select a best combination of oils, 
surfactants, and co-surfactants for SMEDDS formulation, 
component which shown a maximum solubility for 
Dexibuprofen was selected. 
The solubility of Dexibuprofen in different oils and surfactant 
and co-surfactant are shown in figure 4, 5 and 6. The 
solubility study of the Dexibuprofen in different oils reveals 
that Sesame oil, Sunflower oil and oleic acid shows very good 
solubility for Dexibuprofen as compared with other oils as 
shown in figure 4. The surfactants such as Tween 60, Tween 
20 and Tween 80 shows very good solubility for 
Dexibuprofen as compared with other surfactants as shown 
in figure 5. The co-surfactant PEG 600, PEG 400 and Span 20 
shows good solubility than other co-surfactants as shown in 
figure 6. 
 
Figure 4: Solubility of Dexibuprofen in OILS 
 
Figure 5: Solubility of Dexibuprofen in SURFACTANTS 
 
Figure 6: Solubility of Dexibuprofen in CO-SURFACTANTS 
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Preliminary screening of oils, surfactants: 
Oil ( Sesame oil, Sunflower oil, Oleic acid) and Surfactant 
(Tween 60, Tween 20, Tween 80) having good solubilizing 
capacity for Dexibuprofen were selected for the studying 
there micro emulsifying properties. Micro emulsifying ability 
of oils such as Sesame oil, Sunflower oil, and Oleic acid in 
combination with different surfactants such as Tween 60, 
Tween 20 and Tween 80 was determined. 
The micro emulsifying property of Sesame oil in combination 
with Tween 60 rapidly forms micro emulsion but it was 
slightly less clear and forms bluish white appearance and 
forms gel like appearance after 24 hr. Therefore combination 
with Tween 60 will be rejected. While Sesame oil in 
combination with Tween 20 forms rapid micro-
emulsification having clear and slightly bluish appearance 
within 1 min. but it was shows two separate layers after 24 
hr. Therefore combination with Tween 20 will be rejected. 
The micro emulsifying property of Sesame oil in combination 
with Tween 80 rapidly forms microemulsion but it was 
slightly less clear and forms bluish white appearance and 
forms gel like appearance after 24 hr. Therefore combination 
with Tween 80 will be rejected. The micro emulsifying 
property of Sunflower oil in combination with Tween 
60,Tween 20 and  Tween 80 rapidly forms microemulsion 
but it was slightly less clear and forms bluish white 
appearance ,all these combination shows two separate layer 
after 24 hr. Therefore all combination with Sunflower oil will 
be rejected. While Oleic acid in combination with Tween 60 
and Tween 20 forms rapid micro-emulsification having clear 
and slightly bluish appearance within 1 min.  In comparison 
of both the combinations of Oleic acid with Tween 60 and 
Tween 20, the second combination i.e. combination with 
Tween 20 observed less clear than combination with Tween 
60. Therefore combination of Oleic acid and surfactant 
Tween 60 was selected. The micro emulsifying property of 
Olive oil in combination with Tween 80 rapidly forms 
microemulsion but it was slightly less clear and forms bluish 
white appearance, also the Tween 80 combination gives gel 
like appearance after 24 hr. Therefore combination of Oleic 
acid and surfactant Tween 80 was rejected. 
From the above study for preliminary screening of oil and 
surfactant the two combinations were found better involving 
first combination of oleic acid and Tween 60 and second 
combination of oleic acid and Tween 20. As per the solubility 
study of drug in Surfactant  the Tween 60 has more solubility 
than the Tween 20, therefore first combination of oil Oleic 
acid and surfactant Tween 60 were selected for further 
study. 
Preliminary screening of co-surfactant: 
The selected oil phase (Oleic acid) and surfactant (Tween 60) 
are used for screening of the different co-surfactants (PEG 
600, PEG 400, Span 20) for their emulsification ability. The 
emulsifying ability of different combination is shown in table 
8.  
Oleic acid and Tween 60 mixture combination with the 
selected three excipients were studied for their 
emulsification ability and found that the combinations with 
Co-surfactant PEG 600 and PEG 400 shows better micro 
emulsion formation within 1 min. But the combination of the 
co-surfactant Span 20 shows rapidly forming but slightly less 
clear micro emulsion, having a bluish white and PEG 400 
with the oil and surfactant mixture shows phase separation 
after 24 hrs so PEG 400 will be rejected. Further study will 
concluded that the combination of the co-surfactants i.e. PEG 
600 were selected for further study, and it will be used in the 
co-surfactant for the self micro emulsifying system. 
Conclusion from all the above study that finally selected 
components for the SMEDDS formulation of Dexibuprofen 
was given in table 9. 
 
Table 7: Emulsifying properties of oils in combination with different surfactants. 
Oil Surfactant Observation Grade 
 
Sesame oil 
Tween 60 Rapidly forming, slightly less clear microemulsion, having a bluish white. B 
Tween 20 Rapidly forming microemulsion, having a clear or slightly bluish appearance. A 
Tween 80 Rapidly forming, slightly less clear microemulsion, having a bluish white. B 
 
Sunflower oil 
Tween 60 Rapidly forming, slightly less clear microemulsion, having a bluish white. B 
Tween 20 Rapidly forming, slightly less clear microemulsion, having a bluish white. B 
Tween 80 Rapidly forming, slightly less clear microemulsion, having a bluish white B 
 
Table 8: Emulsifying property of different Co-surfactant with selected oil and surfactant 
Oil and Surfactant mixture Co-surfactant Observation Grade 
 
Oleic acid + Tween 60 
PEG 600 A 
PEG 400 A 
Span 20 B 
 
Table 9: Finally selected components for the SMEDDS formulation 
Drug Oil Surfactant Co-surfactant 
Dexibuprofen    Oleic acid Tween 60 PEG 600 
 
Drug-Excipient Compatibility Study 
Visual method 
Drug-excipient compatibility study was done for four week 
at 25oC (RT) and 40oC and samples are visually observed 
initially, after 2 weeks, after 4 weeks for any color change 
and results are shown in table 10.The visual observation 
shows that there is no color change observed during storage 
for four week. 
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Table 10: Visual observation of the drug and excipient 
S. 
N. 
Drug + 
Excipient 
Temp.  Observation  
Initially After 2 Week After 4 Week 
1 Drug + 
Oleic acid 
25oC Clear, Transparent, Yellowish liquid Clear, Transparent, Yellowish liquid Clear, Transparent, Yellowish liquid 
40oC Clear, Transparent, Yellowish liquid Clear, Transparent, Yellowish liquid Clear, Transparent, Yellowish liquid 
2 Drug + 
Tween 60 
25oC Clear, Transparent, Yellowish liquid Clear, Transparent, Yellowish liquid Clear, Transparent, Yellowish liquid 
40oC Clear, Transparent, Yellowish liquid Clear, Transparent, Yellowish liquid Clear, Transparent, Yellowish liquid 
3 Drug + 
PEG 600 
25oC Clear, Transparent, Yellowish liquid Clear, Transparent, Yellowish liquid Clear, Transparent, Yellowish liquid 
40oC Clear, Transparent, Yellowish liquid Clear, Transparent, Yellowish liquid Clear, Transparent, Yellowish liquid 
 
FT-IR Spectroscopic method 
After four week FT-IR of L-SMEDDS samples were taken to 
determine the any functional group change during the 
storage and result are shown in figure 7. The L-SMEDDS FT-
IR of sample placed for compatibility shows the functional 
peaks of Dexibuprofen (drug) at 2924.18,1708.99,1552.24 
cm-1 and no change in functional peaks of drug observed 
after 4 week. 
Visual observation and FT-IR study shows that there is no 
interaction between the drug and excipients selected for the 
formulation of self micro emulsifying system of 
Dexibuprofen.
 
 
Figure 7: Drug excipient compatibility study by FT-IR 
 
 
Evaluation of emulgel 
Physical examination 
The prepared emulgel formulations were inspected visually 
for their color, appearance and consistency.6  
Table 11: Composition of different formulation batches 
(%w/w). 
Ingredient  F1  F2  F3  F4 
Dexibuprofen 1 1 1 1 
Carbapol 940 1 1 1 1 
Oleic Acid 7.5 7.5 7.5 7.5 
Tween 60 0.5 0.5 0.5 0.5 
Span 20 1 1 1 1 
PEG 600 5 5 5 5 
Ethanol 2.5 2.5 2.5 2.5 
Methyl paraben 0.03 0.03 0.03 0.03 
Propyl paraben 0.01 0.01 0.01 0.01 
Sesame Oil - - 8 10 
Clove oil 4 6 - - 
Water q.s. q.s. q.s. q.s. 
 
Rheological study 
The viscosity of the formulated batches was determined 
using a cone and plate viscometer with spindle 7 (Brookfield 
Engineering Laboratories). The assembly was connected to a 
thermostatically controlled circulating water bath 
maintained at 25oC. The formulation whose viscosity was to 
be determined was added to a beaker covered with 
thermostatic jacket. Spindle was allowed to move freely into 
the emulgel and the reading was noted.7 
Spreading coefficient 
Spreading coefficient was determined by apparatus. It 
consists of a wooden block, which is attached to a pulley at 
one end. Spreading coefficient was measured on the basis of 
‘Slip’ and ‘Drag’ characteristics of emulgels. A ground glass 
slide was fixed on the wooden block. An excess of emulgel 
(about 2 g) under study was placed on this ground slide. The 
emulgel preparation was then sandwiched between this slide 
and second glass slide having same dimension as that of the 
fixed ground slide. The second glass slide is provided with 
the hook. Weight of 500 mg was placed on the top of the two 
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slides for 5 min to expel air and to provide a uniform film of 
the emulgel between the two slides. Measured quantity of 
weight was placed in the pan attached to the pulley with the 
help of hook. The time (in s) required by the top slide to 
cover a distance of 5 cm was noted. A shorter interval 
indicates better spreading coefficient.8 
Skin irritation test (patch test) 
A set of 8 rats were used in the study. The emulgel was 
applied on the properly shaven skin of rat. Undesirable skin 
changes, i.e., change in color, change in skin morphology 
were checked for a period of 24 hr.9 
 
 
Table 12: Physical parameters of formulation batches. 
Formulation  Color  Homogeneity  Consistency  Phase separation 
F1 White Excellent Excellent None 
F2 White Excellent Excellent None 
F3 Pale Yellow Excellent Excellent None 
F4 Yellow Excellent Excellent None 
 
 
Bioadhesive strength measurement 
The modified method was used for the measurement of 
bioadhesive strength. The apparatus consist of two arm 
balance. Both the ends are tied to glass plates using strings. 
One side contains two glass plates. Other side contains single 
glass plate for keeping weight. The right and left pans were 
balanced by adding extra weight on the left hand pan. The 
balance was kept in this position for 5 min. Accurately 
weighed 1 g of emulgel was placed between these two slides 
containing hairless fresh rat skin pieces, and extra weight 
from the left pan was removed to sandwich the two pieces of 
glass and some pressure was applied to remove the 
presence of air. The balance was kept in this position for 5 
min. Weight was added slowly at 200 mg/min to the left 
hand pan until the two glass slides got detached from each 
other. The weight (gram force) required to detach the 
emulgel from the glass surface gave the measure of 
bioadhesive strength.10 The bioadhesive strength is 
calculated by using following:  
Biodhesive strength = Weight required (gm) /Area (cm2) 
In vitro release studies 
The in vitro drug release studies were carried out using a 
modified Franz diffusion (FD) cell. The formulation was 
applied on dialysis membrane which was placed between 
donor and receptor compartment of the FD cell. Phosphate 
buffer pH 7.4 was used as a dissolution media. The 
temperature of the cell was maintained at 37oC by 
circulating water jacket. This whole assembly was kept on a 
magnetic stirrer and the solution was stirred continuously 
using a magnetic bead. A similar blank set was run 
simultaneously as a control. Sample (5 ml) was withdrawn 
at suitable time intervals and replaced with equal amounts 
of fresh dissolution media. Samples were analyzed 
spectrophotometrically at 221 nm and the cumulative % 
drug release was calculated. The difference between the 
readings of drug release and control was used as the actual 
reading in each case.11 
Ex vivo drug release study 
The ex vivo drug release study of selected formulations (F2 
and F4) was carried out in a modified Franz diffusion cell, 
using wistar male rat skin. A section of skin was cut and 
placed in the space between the donor and receptor 
compartment of the FD cell, keeping the dorsal side upward. 
Phosphate buffer pH 7.4 was used as dissolution media. The 
temperature of the cell was maintained constant at 32 oC by 
circulating water jacket. This whole assembly was kept on a 
magnetic stirrer and the solution was stirred continuously 
using a magnetic bead. A similar blank set was run 
simultaneously. The samples were withdrawn at suitable 
time intervals and replaced with equal amounts of fresh 
dissolution media.12 Samples were analyzed spectrophoto- 
metrically at 221 nm. 
In vivo anti-inflammatory activity 
Experimental design 
Edema was induced on the left hind paw of the rats by 
subplantar injection of 1% (w/v) carrageenan. 
Formulations, i.e., F2, F4 and standard (diclofenac sodium 
gel) were applied 30 min before carrageenan administration. 
The paw volume was measured at intervals of 30, 60, 90, 
120 min by mercury displacement method using 
plethysmometer.13  
Group 1 (Control group): Carrageenan (1%) was 
administered in the plantar surface of rat. 
Group 2 (Standard group): Topical marketed diclofenac gel 
+ Carrageenan. 
Group 3 (Test): Formulations F2 and F4 + Carrageenan. 
The % inhibition of paw edema in drug treated group was 
compared with carrageenan control group and calculated 
according to the formula: 
% Inhibition of drug = (Vc –Vt) /Vc  x 100 
Where, 
 Vc = inflammatory increase in paw volume control group  
Vt = inflammatory increase in paw volume in (drug 
+carrageenan) treated animals. 
In vivo analgesic activity 
The analgesic activity was carried out using hot plate 
method. Following groups were made and latency period in 
which rat responded to hot plate was calculated Group 1 
(Control Group): No topical treatment was given and 
latency period was calculated. 
Group 2 (Standard Group): The rats were treated with 
diclofenac gel and its latency period was calculated. 
Group 3 (Test Group): The rats were treated with test 
formulations, i.e., F2 and F4 and latency period was 
calculated. 
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Stability studies 
The prepared emulgels were packed in aluminum collapsible 
tubes (5 g) and subjected to stability studies at 5 oC, 25 oC / 
60% RH, 30 oC /65% RH, and 40 oC/75% RH for a period of 3 
months. Samples were withdrawn at 15-day time intervals 
and evaluated for physical appearance, pH, rheological 
properties and drug content.14 
RESULTS AND DISCUSSION 
Physical appearance 
Emulgel formulations were yellowish white viscous creamy 
preparation with a smooth homogeneous texture and glossy 
appearance. Results have been discussed in Table 2. 
Spreading coefficient 
The spreading coefficient of various emulgel formulations 
are given in Fig. 8.  
Rheological studies 
The tests were performed at 100 rpm for 10 min. Results are 
given in Fig. 9. 
Skin Irritation test 
No allergic symptoms like inflammation, redness, irritation 
appeared on rats up to 24 h. 
Biodhesive strength measurement 
The bioadhesive strength of various emulgel formulations 
have been shown in Fig. 10. 
 
 
Figure 8: Spreading coefficient of the formulation F1–F4 
(mean± SD). 
 
 
Figure 9: Viscosity of the formulations F1–F4 (mean± 
SD). 
 
Figure 10: Bioadhesive strength of formulations F1–F4 
(mean ± SD). 
 
In vitro release study 
The study showed the release of the drugs from its 
emulsified gel formulation can be ranked in the following 
descending order: F4 > F1 > F2 >F3 where the amounts of 
the drug release of the drug released after 150 min were 
61.08%, 59.48%, 57.21%, 55.91%, respectively (Fig. 11, 
Table 15). 
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Figure 11: In vitro cumulative % drug release of formulation F1– F4. 
 
 
Ex vivo release study 
This study was carried out only on two best optimized 
formulations. The study showed the release of the drugs 
from its emulsified gel formulation F2 and F4 were 59.45% 
and 61.68%, respectively in 150 min. The results are show in 
Fig. 12.  
 
Figure 12: Ex vivo cumulative % release of formulations 
F2 and F4. 
Anti-inflammatory activity 
The anti-inflammatory action of formulation F2 and F4 was 
calculated and it was compared with diclofenac sodium 
(marketed preparation). The % inhibition of diclofenac 
sodium, F2 and F4 were found to be 64.81%, 58.28% and 
59.62%, respectively. This showed that the formulations 
were as effective as marketed formulation. 
Analgesic activity 
The formulations showed hike in lapse time. They were 
compared with diclofenac sodium gel (marketed 
preparation). 
The lapse time of diclofenac sodium gel, F2 and F4 were 
found to be 6.8 s, 5 s and 5.1 s. 
Stability study 
All the prepared emulgel formulations were found to be 
stable upon storage for 3 months, no change was observed in 
their physical appearance, pH, rheological properties and 
drug content. 
Differential Scanning Calorimetry 
The DSC thermogram of pure Dexibuprofen exhibited a sharp 
endothermic peak at 53.67oC. The DSC of optimized 
formulation not shows any sharp melting peak of 
Dexibuprofen. The absence of sharp melting peak of 
Dexibuprofen at 48.95oC in the DSC of optimized formulation 
indicate that the lipids and aerosil 200 inhibited the 
crystallization of Dexibuprofen i.e. Dexibuprofen is in 
amorphous form or in solubilized form in optimized 
formulation. 
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 (A) 
 
 (B) 
Figure 13: Differential Scanning Calorimetry of (A) Dexibuprofen (B) Optimized Formulation. 
 
Scanning Electron Microscopy 
Scanning electron microscopy (SEM) was used to determine 
the particle morphology of pure drug and optimized 
formulation. The SEM of Dexibuprofen and optimized 
formulation were done and results are shown in figure 14. 
Figure 14 revealed that Dexibuprofen present as crystalline 
powder with cylindrical shaped crystals. The optimized 
formulation shows irregular shaped granular particle. SEM of 
the optimized formulation does not show any cylindrical 
crystals of drug (Dexibuprofen) on the surface of aerosil 200, 
the shape of formulation is spherical and somewhat smooth. 
It indicates that drug is present in the soluble form in lipid 
(SMEDDS formulation), which is adsorbed on the surface of 
aerosil 200. 
 
 
Figure (A) 
 
Figure (B) 
Figure 14: Scanning electron microscopy of (A) Dexibuprofen (B) Optimized Formulation 
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Powder X-ray Diffraction 
The X-ray diffraction pattern of Dexibuprofen and Optimized 
formulation was done and shown in figure 15. 
In the X-ray diffraction pattern of  Dexibuprofen  the sharp 
peaks at a diffraction angle 2Ɵ of 12.46o, 14.12o,14.86o, 
16.83, 17.74o, 19.42o, 20.22o, 22.51, 24.40o, 25.12o, 27.90, 
28.64o,29.56,  31.10o,  32.10o, 34.10o, 35.76o, 36.96o, 37.72o, 
38.68o, 41.16o, 43.94o and 45.22o are present. The presence 
of sharp X-ray diffraction peaks of Dexibuprofen is absence 
in the optimized formulation reveals that drug 
(Dexibuprofen) either present in the amorphous form or 
present in solubilized form in optimized formulation. 
 
 
Figure (A) 
 
Figure (B) 
Figure 15: X- ray Powder Diffraction of (A) Dexibuprofen (B) Optimized Formulation 
 
Stability Study 
Liquid SMEDDS 
The thermodynamic stability study was carried out for 
Liquid-SMEDDS formulation. 
Heating cooling cycle: The liquid SMEDDS was subjected to 
the six cycles between refrigerator temperatures 4ºC and 
45ºC with storage at each temperature for not less than 48 
hours was studied. There is no change found in the 
formulation that means the formulation found stable. 
Centrifugation test: Passed SMEDDS was centrifuged at 
3500 rpm for 30 min using centrifuge (Remi motors Ltd.), 
there was no phase separation found. 
Freeze thaw cycle: Three freeze thaw cycles between -21ºC 
and +25ºC with storage at each temperature for not less than 
48 hours was done for SMEDDS, and it was found stable. 
Solid SMEDDS  
Stability study of optimized formulation at Freeze 
temperature (-20oC), Room temperature (25oC) and High 
temperature (40oC) was done for three month and evaluated 
for following parameters. 
Visual Observation 
Visual observation study (shown in table 13) reveals that 
there is no change in color observed during stability study 
for 3 month. 
 
Table 13: Visual observation data of Optimized formulation for 3 month 
Formulation Temp. Initially Time (months) 
1 month 2 month 3 month 
Optimized 
Formulation 
-20oC White color, 
Odorless powder 
White color, 
Odorless powder 
White color, 
Odorless powder 
White color, Odorless 
powder 
25oC White color, 
Odorless powder 
White color, 
Odorless powder 
White color, 
Odorless powder 
White color, Odorless 
powder 
40oC White color, 
Odorless powder 
White color, 
Odorless powder 
White color, 
Odorless powder 
White color, Odorless 
powder 
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FT-IR 
FT-IR of optimized formulation sample placed at different 
temperature (-20oC, 25oC, 40oC) was done after 3 month to 
determine any change in drug and result is shown in figure 
16. The FT-IR of optimized formulation shows that there is 
no change in the functional peaks of drug (Dexibuprofen) at 
all temperature after 3 months. 
 
 
(Where, A, B and C are FT-IR of optimized formulation sample placed at different temperature -20oC, 25oC, 40oC respectively) 
Figure 16: FT-IR of optimized formulation sample placed at different temperature (A 20oC, B -25oC, C - 40oC) 
 
Drug Content and Emulsifying Property 
Drug content and emulsifying property of optimized 
formulation was done after each month for 3 months and 
results were shown in table 14. The drug content data shows 
that there is no change in drug content of optimized 
formulation. Also no change in emulsifying property of 
optimized formulation was found. 
In-vitro drug release study 
In vitro drug release study of optimized formulation was 
done after 3 month in pH 6.8 phosphate buffer solution.  
 
Table 14: Drug content and emulsifying property of optimized formulation for 3 months 
Parameter Temp. Time (Month) 
1 Month 2 Month 3 Month 
Drug Content -20oC 98.23 98.43 98.43 
25oC 98.82 98.82 98.62 
40oC 98.43 98.62 97.84 
Emulsifying 
Property 
-20oC Disperse uniformly to form micro 
emulsion instantly 
Disperse uniformly to form 
micro emulsion instantly 
Disperse uniformly to form 
micro emulsion instantly 
25oC Disperse uniformly to form micro 
emulsion instantly 
Disperse uniformly to form 
micro emulsion instantly 
Disperse uniformly to form 
micro emulsion instantly 
40oC Disperse uniformly to form micro 
emulsion instantly 
Disperse uniformly to form 
micro emulsion instantly 
Disperse uniformly to form 
micro emulsion instantly 
 
Table 15: Data for in vitro cumulative % drug release data of formulations F1–F4. 
Time (Min) F1 F2 F3 F4 
0 00.00 ± 0.00 00.00 ± 00.00 00.00 ± 00.00 00.00 ± 00.00 
5 11.91 ± 00.01 10.02 ± 08.65 10.82 ± 06.83 13.55 ± 30.44 
15 12.23 ± 00.05 16.93 ± 09.24 14.54 ± 13.30 17.76 ± 10.21 
30 16.19 ± 01.30 22.13 ± 06.83 10.44 ± 10.2 19.22 ± 15.72 
60 38.05 ± 31.70 39.95 ± 24.70 42.14 ± 00.38 39.82 ± 00.03 
90 43.63 ± 31.70 41.56 ± 03.10 41.64 ± 07.55 47.02 ± 03.12 
120 48.01 ± 07.55 49.38 ± 02.80 47.44 ± 03.10 56.72 ± 13.34 
150 59.48 ± 02.85 57.21 ± 02.21 55.91 ± 00.49 61.08 ± 02.34 
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CONCLUSION 
In the coming years, topical drug delivery will be used 
extensively to impart better patient compliance. Since 
emulgel is helpful in enhancing spreadability, adhesion, 
viscosity and extrusion, this novel drug delivery become 
popular. Moreover, they will become a solution for loading 
hydrophobic drugs in water soluble gel bases for the long 
term stability. Similarly in the study, topical emulgels of 
Dexibuprofen were formulated and subjected to 
physicochemical studies i.e. rheological studies, spreading 
coefficient studies and bioadhesion strength, in vitro release 
studies and ex vivo release studies through rat skin. In vitro 
release of the tests formulations were performed to 
determine drug release from emulgel rate and duration of 
drug release. From the in vitro studies, formulation F4 
showed maximum release of 61.08% in 150 min. Ex vivo 
drug release was also performed in which formulation F4 
showed best release of 61.68% in 150 min. Carrageenan 
induced paw edema and hot plate tests revealed anti-
inflammatory and analgesic activity. The formulations F2 and 
F4 were comparable with marketed diclofenac topical gel. So 
Dexibuprofen emulgel can be used as an anti-inflammatory 
analgesic agent for topical drug delivery.  
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